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have been either ventricular tachycardia or ventricular tibril- 
lation. However, patients whose clinical arrhythmi: 4~ -fen- 
tricular fibrillation may represent a unique group with dif- 
ferent clinical and electrophysiologic characteristics from 
those of patients whose clinical arrhythmia s sustained 
ventricular tachycardia (1,7). 
The use of more aggressive pacing protocols during 
electrophysiologic studies (such as three or more pro- 
grammed extrastimuli, infusion of isoproterenol or pacing 
from the left ventricle) may produce “nonclinical” arrhyth- 
mias, such as polymorphic nonsustained ventricular tachy- 
cardia or ventricular fibrillation (10-16). It is unclear 
whether inducible ventricular fibrillation should be charac- 
terized as a nonspecific end point of electrophysiologic 
studies in survivors of cardiac arrest whose first documented 
arrhythmia was ventricular fibrillation. That is, if the pre- 
senting arrhythmia was ventricular fibrillation, is induced 
ventricular fibrillation a nonclinical rhythm? Similarly, the 
clinical course of patients with only inducible nonsustained 
ventricular tachycardia is not known. Therefore, the prog- 
nostic significance of inducible sustained ventricular tachy- 
cardia, ventricular fibrillation, nonsustained ventricular 
tachycardia or noninducibility exclusively insurvivors of out 
of hospital ventricular fibrillation was evaluated in this 
study. 
Study patients. The study group consisted of 241 survi- 
vors of out of hospital sudden cardiac death evaluated atthe 
University of Washington (134 patients), Oregon Health 
Sciences University (73 patients) and Stanford University 
Medical Center (34 patients) who underwent baseline drug- 
free electrophysiologic testing. Patients were entered into 
the study between May 1983 and December 1987. No patient 
had experienced a myocardial infarction within the previous 
6 weeks and no patient had evidence of a new transmural (Q
wave) myocardial infarction at the time of cardiac arrest. All 
patients had experienced sudden loss of consciousness as- 
sociated with circulatory collapse in a previously stable 
clinical setting. The first rhythm documented at the time of 
cardiac arrest in all patients was ventricular fibrillation. 
Patients were excluded if the first rhythm on arrival of the 
paramedics was sustained ventricular tachycardia, which 
subsequently degenerated to ventricular fibrillation. There- 
fore, this study represents 241 consecutive survivors of 
cardiac arrest in whom the presenting arrhythmia was ven- 
tricular fibrillation. 
Ektmphysiologic study protocol. Before electrophysio- 
logic studies were begun, antiarrhythmic drugs were discon- 
tinued for a period of at least five half-lives or until 
drug levels were negligible. No patient had previousi 
given amiodarone. After each patient’s informed c
multipolar recording and stimulation catheters we 
tioned in the right atrium, right ventri 
bundle. Surface lectrocardiographic 
corded simultaneously with the intr 
The protocol for all patients in&d 
premature extrastimuli from two rigb 
ally the right ventricular pex and rigbt ventric 
tract) at two basic drive cycle len 
ms) using a 2 ms rectangular 
diastolic threshold. The end poi 
completion ofthe basic protocol 
stimuli or in~Mct~om of a sustaine 
Inducible ventricular fibrillation was 
morphic ventricular arrhythmia with a 
5200 ms that lasted ~30 s or re 
tion. Tbe cycle length of the arrhythmia was mea- 
sured after the first 10 QRS c s. Inducible sustained 
ventricular tachycardia was defined as an organized ventric- 
ular arrhythmia with a cycle length >200 ms that lasted 
230 s or required cardioversion for hemodynamic compro- 
mise. Inducible nonsustained ventricular tachycardia was 
defined as ventricular tachycardia (monomorphic or
morphic) that lasted 530 3 but included more than five 
complexes. A patient’s arrhytbmia was considered nomiu- 
ducible ifonly five or fewer ventricular reentrant beats could 
be induced. 
Eighty-eight percent of patients with inducible sustaine 
ventricular rhythmias underwent serial electrophysiologi- 
tally guided antiarrhythmic drug studies. Successful sup- 
pressioa of inducible arr ias during drug testing was 
defined as the inability to induce a sustained ventricular 
arrhythmia with a stimulation protocol identicr.J to that 
described for drug-free studies. 
Clnical variables. The clinical variables evaluated in- 
cluded age, gender, ejection fraction measured by radionu- 
elide ventricutography (or,when not available, by contrast 
angiographic left ventriculography), underlying structural 
heart disease, history of prior myocardial infarction, pres- 
ence of clinical congestive heart failure defined by New York 
Heart Association criteria nd a history of prior sustained 
ventricular rhythmias. Treatment included antiarrhythmic 
drug therapy, surgical procedures and placement of an 
automatic implantable cardioverter-defibrillator (AICD). 
Follow-up. The mean duration of follow-up for the pa- 
tients was 30 t 15 months; only four patients (1.7%) were 
lost to follow-up. The end points evaluated were total 
mortality, recurrent sudden cardiac death, nonfatal ventric- 
ular fibrillation and recurrent sustained ventricular tacbycar- 
dia. Sudden cardiac death was defined as sudden and unex- 
pected circulatory collapse in a patient who was previously 
clinically stable. Nonfatal ventricular fibrillation was defined 
as sudden cardiovascular collapse occurring in a patient 
successfully resuscitated and in whom the first documented 
rhythm was ventricular fibrillation. This definition was ex- 
tended to include patients with an AICD who received a
Number of 
remature Sustained VT VF NSVT 
Extrastimuli (n = 6%) ln = 39) bl = 348 
2 35 (53%) 19 (4!m i7 (50%) 
3 20 E3O%oi 15 mm 16 (47%) 
4 s (8%‘n) I l3%J) I (3%) 
NSVT = no~susta~~e~ ve~trie~~r tachycardia: VF = ve~t~ic~~~r ~~~il~~- 
tion; VT = ventricular tachycardia. 
iologic testing. Thirty 
reentrant ventricular t 40 s of ventricular tachy- 
cardia; 102 patients ( five or fewer ~~d~c~b~e reen- 
inducible. In 10 of these 39 patients the average cycle length 
cardia group. 
The number of ~re~at~~e ve~ltr~~~~~~~ e~t~~~ti~~i4~i TV- 
quired to induce a ventricular a~r~~yt~~mio is shown ill 
Table 1. When statistical co~parjs~~s were made between 
patients with inducible sustained ventricular tachycardia and 
the other groups. The average age was comparable along 
the patient groups. A remote history of sustained ve~t~c~la~ 
ardia or ventricular ~b~il~ation was present in 23% of 
therapy in all patients was suppression if i~dacib~e smtained 
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Table 2. Clinical Characteristics of 241 Study Patients 
Inducible Inducible 
Sustained VT VF 
(n = 66) (r-l = 39) 
inducible NSVT 
tn = 34) 
Noninducible 
(n = 102) 
Age tyr) 59 f 13 562 I2 60 + 41 59 k 14 
Ejection fraction 0.31 0.42 0.43 0.43 
Gender 
Male 
Female 
No organic heart disease 
Coronary artery disease 
Dilated cardiomyopathy 
Hypertrophic cardiomyopathy 
Hypertension alone 
Aorticlmitral valve disease 
Right ventricular dysplasia 
Prior Q wave 
myocardial infarction 
Clinical congestive heart failure 
NYHA functional class 
I 
I1 or 111 
IV 
Remote history of sustained 
ventricular arrhythmia 
Sustained VT 
Sustained VF 
Treated with antiarrhythmic 
medication at the time of 
cardiac arresl 
63 (%%I 30 (77%) 26 (76%) 75 (74%) 
3 (4%) 9 (23%) 8 (24%) 27 (26%) 
2 (3%) 2 (5%) 0 (0%) 8 (6%) 
54 (82%) 26 (67%) 19 (56%) 68 (67%) 
7(11%) 8 (21%) 7 (21%) 114 ( 14%) 
0 (0%) 2 (5%) I (3%) 1(1%) 
0 (0%) I (3%) 2 (6%) 3 (3%) 
2 (3%) 0 (0%) 4 (12%) 4 (4%) 
I(I%) 0 (0%) I (3%) 4 (4%) 
47 (71%) I5 (39%) 14 (41%) 28 (28%) 
23 (35%) 29 (74%) 16 147%) 50 (49%) 
43 (65%) IO (26%) IS 153%) 34 t33%‘0) 
0 (0%) 0 (0%) 0 too/o1 I (1%) 
9 (14%) 5 (13%) I8 124%) 7 (7%) 
6 (9%) 2 (5%) 4 02%) 0 ID%) 
8 (12%) 3 (8%) I3 (38%) 14 (14%) 
NYHA = New York Heart Association; other abbreviations as in Table I. 
arrhythmias. If this goal was not possible, patients were 
evaluated for treatment with amiodarone, surgery or an 
AICD. However, in 13 patients inducible sustained ventric- 
ular tachycardia was slow and well tolerated on repeat drug 
testing. Because amiodarone and cardiac surgery were not 
options, at discharge these patients were given the antiar- 
rhythmic drug shown to be partially successful during repeat 
electrophysiologic testing. Also, in two patients rapid and 
poorly tolerated inducible nonsustained ventricular tachy- 
car&a was not an acceptable end point of drug testing, and 
amiodarone was administered. 
Table 3 shows thefinal antiurrhylhmic drug chosen for all 
patients at the time of discharge from the hospital. 
than 90% of patients with inducible sustained ventricular 
arrhythmias were treated with an antiarrhythmic drug. For- 
ty-seven percent of patients without inducible sustained 
arrhythmias also underwent serial 24 h ambulatory ECG 
recordings for monitoring of frequent symptomatic nonsus- 
Table 3. Antiarrhythmic Drugs at Hospital Discharge in 241 Patients 
No drug 
Class IA 
Class IB 
Class IC 
Class I combination 
Amiodarone 
Amiodarone and class 1 combination 
Abbreviations as in Table I. 
inducible 
Sustained VT 
fn = 66) 
6 (9%) 
I5 (23%) 
I (2%) 
8 (12%) 
5 (7%) 
30 (45%) 
I (2%) 
Inducible 
VF 
tn = 39) 
5 (10%) 
18 (46%) 
I (3%) 
3 (8%) 
I (2%) 
9 (23%) 
3 (8%) 
inducible 
NSVT 
tn = 34) 
IO (30%) 
I I (32%) 
3 (9%) 
I (3%) 
I (3%) 
8 (23%) 
0 WI9 
Noninducible 
tn = 102) 
62 (61%) 
I7 (17%) 
4 (4%) 
6 (6%) 
I2 (II%) 
I(I%) 
0 (0%) 
September l~9~65?-65 
Pnducibte tnducible lnduciblc 
Sustained VI’ NSVT Noninducibir 
(n = 66) In = 39) tn = 34) (n = tO?t 
6 (9%) 8 (20%) 9 t26’Xt 26 (25% b 
IO (15%) 12 (31%) 5 (15%) 9 (9%) 
VT surgery 6 69%) 2 (5%) 0 (0%) I(m) 
Total’ 17 (26%) 1x (46%) 14 (41%) 36 (35%) 
*Many patients underwent multiple procedures. CARG = coronary artery bypass grafting: VT surgery = 
endocardial resection or cryoablation. or both: other abbreviations as in Table I. 
ore often in patients 
induced (p = 0.01). Of the 34 patients who had received an 
AICD, 4 had sudden cardiac death, d other cardiac death 
and 5 had either documented A shocks because of 
cumulative survival rate was 77 
a-free survival rate was 95%. Fi 
among patients with noninducible arrhythmia (p = 0.12). 
Arrhythmia-free survival (Fig. 3) was significantly better in 
patients without (81%) than in those with (65%) inducible 
Table 5. Recurrent Arrhythmia and Death on Follow-Up in 241 Patients 
inducible Inducible inducible 
Sustained VT Sustained VF NSVT Noninducible 
(n = 66) tu = 39) tn = 34) tn = 102) 
Sudden cardiac death 10 ttL?%‘r) 7 (18%) 3 (9%) I2 t1298 
Resuscitated VF* 4 (6%) 4 (10%) I (3%) 4 (4%) 
Recurrent sustained VT: 8 (12%) 2 (5%) 2 (6%) IlI%) 
Other cardiac death 8(12%) 2 (5%) 3 (9%) 6 (6%) 
Noncardiac death I (2%) I (3%) 3 (9%) ItI%) 
*Includes six patients who received a shock from an ARID preceded by loss of consciousness. +lncludes six 
patients who received a shock from an AICD preceded by near loss of consciousness. Abbreviations as in Table 1. 
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Figure 1. Survival curves for all 241 patients. Cumulative survival is 
defined as alive without sudden cardiac death, other cardiac death, 
resuscitated ventricular fibrillation (VF) and automatic implantable 
cardioverterdefibrillator (AICD) shocks preceded by loss of con- 
sciousness. Arrhythmia-free survival is defined as alive without 
sudden cardiac death, other cardiac death, resuscitated ventricular 
fibrillation, recurrent sustained ventricular tachycardia or AICD 
shocks preceded by loss of consciousness or near loss of conscious- 
ness. The curve labeled recurrent sudden cardiac death/VF excludes 
other cardiac death, recurrent sustained ventricular tachycardia and 
AICD shocks associated with near loss of consciousness as end 
points. 
sustained ventricular tachycardia or inducible ventricular 
fibrillation (71%) or inducible nonsustained ventricular 
tachycardia (79%) (p = 0.02). No statistical difference was 
noted when only patients with inducible sustained ventricu- 
lar tachycardia were compared with those with inducible 
ventricular fibrillation (p = 0.6). Furthermore, no statisti- 
cally significant differences were found between patients 
with inducible nonsustained ventricular tachycardia and 
those without inducible arrhythmias when compared individ- 
ually (p = 0.69). 
!3erial eleetrophysiologic studies. In 92 (88%) of the 105 
patients with inducible sustained ventricular tachycardia or 
inducible ventricular fibrillation who underwent serial drug 
testing with use of electrophysiologic studies, the arrhythmia 
was subsequently rendered noninducible with a class 1 
antiarrhythmic drug in 44 (48%) (Fig. 4). Arrhythmia-free 
survival was not improved inthe patients whose arrhythmia 
was successfully suppressed by electrophysiologically 
guided therapy (p = 0.95). However, 71% of the 48 patients 
whose arrhythmia was not suppressed were treated with 
anGxkone and did not undergo repeat electrophysiologic 
testing while taking the drug; these patients were included in 
Figure 2. Cumulative survival in 241 patients stratified by inducibil- 
ity of arrhythmia at baseline drug-free electrophysiologic testing. 
Cumulative survival is defined as alive without sudden cardiac 
death, other cardiac death, resuscitated ventricular fibrillation (VF) 
or automatic implantable cardioverter-defibrillator shocks preceded 
by loss of consciousness. VT = ventricular tachycardia. 
the nonsuppressed group in this analysis. If these patients 
are excluded, the results are unchanged, although the num- 
ber of patients hen remaining inthe nonsuppressed group is 
Figure 3. Arrhythmia-free survival in 241 patients. Arrhythmia-free 
survival is defined as in Figure I. VF = ventricular fibrillation: 
VT = ventricular tachycardia. 
- Induel VF (m36) 
I--- Nonlnduclblo (nd2) 
pro.02 
I I I I I 
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~r~~yth~~a-~ree survival of 92 patients with inducible 
ventricular tachycardia or ventricular ~~~i~iat~on t base- 
~tric~lar tacbycard~a we 
tbe 241 patients to assess their ability to 
independently (Table 6). The only indepen 
poor outcome after muit~variate analysis was 
predictor of outcome, actuarial a was done with 
patients stratified according to their ntricular function. 
An ejection fraction above or below 0.30 was found to best 
stratify the patients’ outcome (Table 7). Patients 
s noninducible but who had an ejectio 
parable to that of p 
le sustained ventricular tachycardia or ventric- 
on who also bad a low ejection fraction. 
e same stratification was used to analyze the patients 
with inducible sustained ventricular tachycardia or ventric- 
ular fibrillation that had been suppressed or not suppressed 
by electrophysiologically guided drug therapy. A statistically 
significant difference was not observed among the patients 
not sustaine 
from patients with sustained ventricular tachycardia (1.71, 
and it is important to distinguish between them. 
Our rate of inducible sustained ventricular arrhythmias 
(44%) is s~6~~~cantly lower 
studies of cardiac arrest survi 
patients with inducible nonsustained vent 
in our definition of i 
reports do, our indu be 57%. This rate is 
sti!l lower than that of other reps 
selection in our study, which e 
sustained ventricular tachycardi 
Q&RN stndkss. Several stud 
arrhythmias in survivors of cardiac arrest. In the study of 
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Table 7. Actuarial Survival of 224 Patients Stratified by Left Ventricular Ejection Fraction* 
Inducible Sustained VT Inducible VF Inducible NSVT Noni~~Mci~le 
(n = 63) (n = 38) (n = 321 (n = 91) 
EF > 0.30 EF = 0.30 EF > 0.30 EF = 0.30 EF > 0.30 EF 5 0.30 EF > 0.30 EF s 0.30 
(n = 27) (n = 36) (n = 26) (n = 12) (n = 21) (n = II) (n = 61) (n = 30) 
I year cumulative 80% 77% 85% 65% 89% 85% 98% 99% 
survival 
2 year cumulative 77% 62% 81% 56% 86% 81% 89% % 
survival 
p = 0.20 p = 0.05 p = 0.70 
*Three of66 patients with inducible sustained ventricular tachycardia (VT). I of 39 patients with inducible ventricular fibrillation (VF). 2 of 34 patients with 
inducible nonsustained ventricular tachycardia and I I of 102 patients in whom arrhythmia was not inducible had no assessment of left ventricular ejection fraction. 
Abbreviations as in Table I I 
Freedman et al. (4) the nature of the inducible rhythm at 
baseline, whether nonsustained ventricular tachycardia, SUS- 
tained ventricular tachycardia or ventricular fibrillation, for 
instance, was not associated with significant prognostic 
value. However, inducibility was a powerful predictor of 
outcome. Our study found a better survival rate in patients 
without compared with those with inducible sustained ar- 
rhythmias; however, inducibility at baseline electrophysio- 
logic testing was not an independent predictor of outcome. 
Similarly, in the study of Wilber et al. (6) baseline inducibil- 
ity was not found to be an important independent 
of outcome. In that study independent predictors of outcome 
included persistence of inducible ventricular tachycardia 
during treatment, an ejection fraction ~0.30 and lack of 
cardiac surgery. In contrast, we did not find that persistence 
of inducible arrhythmias was an important prognostic factor. 
Our data, however, are complicated by differences in treat- 
ment and the fact that most patients treated with amiodarone 
did not undergo repeat electrophysiologic testing and were 
included in the nonsuppressed group. It is possible that 
survival may be improved in amiodarone-treated patients to 
a degree equal to that of patients whose arrhythmia is 
successfully suppressed with a class I antiarrhythmic drug. 
Alternatively, the sample size in this study may have been 
too small and, therefore, the statistical power to identify a 
positive (or negative) outcome may have been lacking. It 
should also be considered that electrophysiologically guided 
drug testing in survivors of out of hospital ventricular 
fibrillation may not be as useful as it is in patients whose 
clinical arrhythmia is sustained ventricular tachycardia. 
We found that survival in patients with inducible ventric- 
ular fibrillation issimilar to survival in patients with induc- 
ible sustained ventricular tachycardia. Previous studies (lo- 
13) have suggested that inducible ventricular fibrillation may 
be one of several unimportant, nonclinical responses to 
programmed stimulation with use of an aggressive pacing 
Protocol in patients without a prior history of ventricular 
arrhythmias. However, in patients with a history of prior 
ventricular arrhythmias, inducibility of ventricular fibrilla- 
tion may be significant. Spielman et al. ( 
incidence rate of inducible ventricular fib~l~ation a 
patients, many of whom b 
ular arrhythmias. All of th 
fibrillation was induced had a prior hi 
arrhythmias. Furthermore, re~~rre~~e 
lation in these IO patie 
population differs from 
because all patients wer 
arrest resulting from documented ventricula 
noted a much higher incidence of inducible ventricular 
with inducible sustained ventricular arrhyt 
only inducible ventricular fibrillation. The h 
of inducible ventricular fib~llatio~ in our study may also be 
related to a pacing protocol that included three pre 
ve 
tients with inducible ventricular fibrillatio 
our study and their survival did not d 
patients with inducible sustained ventricular tachycardia, 
survival was predicted solely by the status of a patient’s left 
ventricular function. Only the presence of clinical congestive 
heart failure in a logistic regression model was found to be an 
independent predictor of poor outcome. This finding 
prompted further analysis of the patient subgroups stratified 
by left ventricular ejection fraction. Survival among patients 
with inducible ventricular fibrillation and an ejection fraction 
20.30 was better than that among patients with inducible 
sustained ventricular tachycardia and an ejection fraction 
~0.30. However, patients with i~dMcible ventricular fibri~~a- 
tion and an ejection fraction ~0.30 have a much lower 2 year 
cumulative survival rate of only 56%. This observation may 
explain the lack of overall difference in survival between 
patients with inducible sustained ventricular ~acbycardia and 
inducible ventricular fibrillation, despite the finding that 
patients with inducible ventricular fibrillation as a whole had 
improved markers of left ventricular function when com- 
may not be as useful a 
~~~t~i~~~ar fibrillati 1.5 whose clinical 
the need for aatiarr 
recurrence rates of 
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